Essential Phospholipids: Interactions With Other Medicines
Essential phospholipids, purified from soya beans, are sold in many countries as a liver medicine and in the UK mainly as food supplements. They are widely regarded as gentle, but 'gentle' does not mean free of interactions. Our editorial team reviews what is documented about combining essential phospholipids with other medicines and supplements.
What essential phospholipids are
Essential phospholipids (EPL) are a highly purified extract of soya bean phospholipids, rich in polyenylphosphatidylcholine (PPC). The dominant molecule is 1,2-dilinoleoylphosphatidylcholine, a form of phosphatidylcholine carrying two linoleic acid chains.
Phosphatidylcholine is a major structural component of cell membranes, including those of liver cells. The theory behind EPL is that supplying these molecules helps repair damaged membranes, influences lipid metabolism and reduces oxidative stress in the liver.
In parts of Europe, Asia and Latin America, EPL is registered as a medicine for conditions such as fatty liver disease. In the UK it is not a licensed medicine, and products containing phosphatidylcholine or lecithin are sold as food supplements without authorised liver health claims.
Clinical evidence is mixed. Some trials and reviews, often industry-supported, report improvements in liver enzymes and steatosis on imaging, while independent high-quality evidence for hard outcomes such as cirrhosis prevention is limited.
Anticoagulants: the main documented caution
The most frequently cited interaction concerns anticoagulants. Product information for registered EPL medicines in several countries states that an interaction with anticoagulants cannot be ruled out and that dose adjustment of the anticoagulant may be needed.
The mechanism is not fully established. Phospholipids participate in the coagulation cascade on cell surfaces, and changes in lipid metabolism could theoretically influence how anticoagulants work. Clinical reports of significant bleeding are rare, but caution is still recommended.
For people on warfarin, any new supplement can affect INR stability. Those on direct oral anticoagulants or antiplatelet drugs are less likely to experience a measurable interaction, but they should inform their GP or pharmacist about all supplements.
| Medicine or substance | Possible issue | Suggested action |
|---|---|---|
| Warfarin and other vitamin K antagonists | Possible change in anticoagulant effect | Discuss with anticoagulation clinic; monitor INR |
| Direct oral anticoagulants | Interaction not well studied | Inform prescriber |
| Antiplatelet drugs | Theoretical additive effect with other supplements | Review total supplement intake |
| Liquid forms with alcohol | Interaction with disulfiram, metronidazole | Check excipients |
| Soy allergy | Allergic reactions | Avoid |
Other medicines, supplements and liver drugs
EPL is often combined with other 'liver support' products such as milk thistle (silymarin), UDCA, TUDCA or artichoke extract. No specific harmful interactions are well documented, but combining several active agents complicates interpretation of liver blood tests and side effects.
People taking statins or other lipid-lowering medicines sometimes ask whether EPL interferes with them. There is no strong evidence of a clinically significant interaction, although lipid profiles should be monitored as part of routine care.
Some formulations contain vitamin E or B vitamins. If you already take a multivitamin or other supplements, check total intake, especially of vitamin E, which at high doses may itself affect bleeding risk.
Unlike many herbal extracts, phosphatidylcholine is not known to strongly affect cytochrome P450 enzymes. This makes broad metabolic interactions unlikely, but the absence of evidence is partly due to limited research.
Excipients and special formulations
Interactions do not always involve the active ingredient. Some liquid or injectable formulations historically contained benzyl alcohol or ethanol as solvents. Alcohol-containing products may interact with disulfiram or metronidazole and are unsuitable for people avoiding alcohol.
Capsules usually contain soybean oil and may include gelatin, which matters for vegetarians and for some religious dietary practices. Colourings and other excipients are listed on the label and should be checked by people with known sensitivities.
Soy allergy is an absolute reason to avoid EPL. Although purification reduces protein content, trace soy proteins may remain. Soya is one of the 14 major allergens that must be highlighted on UK food labels.
- Check for soy allergy before use.
- Read excipients for alcohol, gelatin and colourings.
- Avoid combining multiple products containing vitamin E without checking totals.
- Prefer products with clear dose statements and batch numbers.
Who should seek advice before use
People with diagnosed liver disease should discuss EPL with their hepatologist or GP. Self-treatment can delay proper assessment, and the underlying cause of abnormal liver tests, such as alcohol, viral hepatitis or metabolic disease, needs specific management.
Pregnant and breastfeeding women, children and adolescents should avoid EPL supplements unless advised by a doctor, because safety data in these groups are limited.
People taking several medicines, especially older adults, benefit from a pharmacist medicines review. In the UK this is available through community pharmacies and can help identify unnecessary or potentially interacting supplements.
Finally, EPL is not a protective shield against alcohol or hepatotoxic drugs. Reducing alcohol, achieving a healthy weight and avoiding unnecessary hepatotoxic substances remain the most effective ways to protect the liver.
Editorial conclusions
Essential phospholipids are generally well tolerated, but they are not entirely free of interactions.
The main documented caution concerns anticoagulants, especially warfarin, while soy allergy and alcohol-containing formulations are other important considerations.
Tell your doctor or pharmacist about any EPL product, and do not use it as a substitute for diagnosing and treating liver disease.
Our editorial team suggests reading next about milk thistle and the liver, UDCA effects on the liver and kidneys, and how to interpret liver function tests.
References
- Gundermann KJ, Kuenker A, Kuntz E, Droździk M. Activity of essential phospholipids (EPL) from soybean in liver diseases. Pharmacol Rep. 2011;63(3):643–659.
- Gundermann KJ, Gundermann S, Drozdzik M, Mohan Prasad VG. Essential phospholipids in fatty liver: a scientific update. Clin Exp Gastroenterol. 2016;9:105–117.
- Lieber CS, Weiss DG, Groszmann R, et al. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):1765–1772.
- Dajani AI, Abu Hammour AM, Zakaria MA, et al. Essential phospholipids as a supportive adjunct in the management of patients with NAFLD. Arab J Gastroenterol. 2015;16(3–4):99–104.
- Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018;67(1):328–357.
- Holbrook AM, Pereira JA, Labiris R, et al. Systematic overview of warfarin and its drug and food interactions. Arch Intern Med. 2005;165(10):1095–1106.
